Abstract
Settings Our centre is a public referral and treatment centre situated in the Chennai
metropolis. The analysis of the number of women diagnosed with cervical cancer at our centre was performed to find out the impact of low-cost cervical cancer screening in bringing down the incidence of cervical cancer.
Aim To find out the number of women diagnosed with cervical cancer over the past 3 years from 2011 to 2013, in a referral centre in Chennai, to assess the impact of the ongoing cervical cancer screening program.
Methods The number of women diagnosed with cervical cancer and gynaecological cancer from 2011 to 2013 were noted from the records of histopathological reports and maintained in the colposcopy and pathology departments.
Results In 2011, the number of women diagnosed with cervical cancer was 782. The majority of 739 women had squamous cell carcinoma and a less number of 43 women had adenocarcinoma. The following year 2012, the number of women with cervical
cancer showed a promising decrease to a total of 672, and further decreased to 599 in 2013. Squamous cell carcinoma was diagnosed in 655 women in 2012 and 575 women in 2013. In the year 2011, the number of women with squamous cell cancer was larger in the age group of 50–60 years, and the largest numbers of women with adenocarcinoma were in the age group of 41–50 years. There was a significant reduction in the incidence of cervical cancer in all the 3 years (P < 0.0000001). A fall in the percentage of cervical cancer among total gynaecological cancers was also observed.
Conclusion A significant reduction was observed in the incidence of cervical cancer over the past 3 years. The ongoing State Cervical Cancer Screening program could probably have contributed to effect this change.
Keywords
References
Obel J, Souares Y, Hoy D, Baravilala W, Garland SM, Kjaer SK, et al. A systematic review of cervical cancer incidence and mortality in the Pacific region. Asian Pac J Cancer Prev. 2014;15(21):9433–7.
Hussain SA, Sullivan R. Cancer control in Bangladesh. Jpn J Clin Oncol. 2013;43(12):1159–69.
Franceschi S, Wild CP. Meeting the global demands of epidemiologic transition: the indispensable role of cancer prevention. Mol Oncol. 2013;7(1):1–13.
Nicole GC, Vivien T, Jeronimo J, Mercy M, Kyueun L, Jane JK. When and how often to screen for cervical cancer in three lowand middle-income countries: a cost-effectiveness analysis. Papillomavirus Res. 2015;01:38–58.
Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, et al. Comprehensive control of HPV infections and related diseases. Vaccine. 2013;31(7):H1–H31.
Raychaudhuri S, Mandal S. Current status of knowledge, attitude and practice (KAP) and screening for cervical cancer in countries at different levels of development. Asian Pac J Cancer Prev. 2012;13(9):4221–7.
von Karsa L, Arbyn M, De Vuyst H, Dillnerd J, Dillnere L, Franceschi S, et al. European guidelines for quality assurance in cervical cancer screening: summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 2015;1:22–31.
Arbyn M, Fisher A, Martin-Hirsch PPL, Zhao FH, Qiao Y. Low cost versus other screening tests to detect cervical cancer or precancer in developing countries. Cochrane Database Syst Rev. 2012;11:CD010186.
Hartwig S, Baldauf JJ, Dominiak-Felden G, Simondonc F, Alemanyd L, de Sanjosé S, et al. Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines. Papillomavirus Res. 2015;1:90–100.
Sylla BS, Wild CP. A million Africans a year dying from cancer by 2030: what can cancer research and control offer to the continent? Int J Cancer. 2012;130(2):245–50.
Refbacks
- There are currently no refbacks.
Copyright (c) 2016 Journal of Pharmaceutical and Biomedical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.